Financial reports
Current reports
8-K
Completion of Acquisition or Disposition of Assets
22 Jan 21
8-K
Lilly Announces Agreement to Acquire Prevail Therapeutics
15 Dec 20
8-K
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
13 Nov 20
8-K
Regulation FD Disclosure
12 Nov 20
8-K
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
2 Nov 20
8-K
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
10 Sep 20
8-K
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
11 Aug 20
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 20
8-K
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights
14 May 20
8-K
Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
26 Mar 20
Registration and prospectus
15-12B
Securities registration termination
1 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
POS AM
Prospectus update (post-effective amendment)
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
22 Jan 21
25-NSE
Exchange delisting
22 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
20 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
20 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
14 Jan 21
Other
EFFECT
Notice of effectiveness
27 Jan 21
UPLOAD
Letter from SEC
4 Jan 21
EFFECT
Notice of effectiveness
9 Jul 20
UPLOAD
Letter from SEC
7 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
EFFECT
Notice of effectiveness
20 Jun 19
SEC STAFF
SEC staff action: Order
18 Jun 19
CORRESP
Correspondence with SEC
17 Jun 19
CORRESP
Correspondence with SEC
17 Jun 19
CERT
Certification of approval for exchange listing
13 Jun 19
Ownership
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
16 Feb 21
SC 13G/A
CITADEL ADVISORS LLC
16 Feb 21
SC 13G/A
EcoR1 Capital, LLC
12 Feb 21
SC 13G/A
REGENXBIO Inc.
12 Feb 21
SC 13G
JNE Partners LLP
29 Jan 21
SC 13D/A
ORBIMED ADVISORS LLC
29 Jan 21
4
Change in insider ownership
26 Jan 21
4
Asa Abeliovich
26 Jan 21
4
Timothy M Adams
26 Jan 21
4
William H. Carson
26 Jan 21